Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Efficacy and Safety of Venetoclax in Combination With Ibrutinib in Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma

NCT04477486 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04477486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04477486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Efficacy and Safety of Venetoclax in Combination With Ibrutinib in Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
September 23, 2020
Completion date
May 28, 2025
Enrollment
13 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)